• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Jan. 30

Aurobindo Pharma Ltd has announced that the US Food and Drug Administration (USFDA) has approved its API (Active Pharmaceutical Ingredient) facility at Unit-VI to manufacture sterile ceftiofur sodium. This facility is situated on a 15-acre land in Chitkul village, Patancheruvu mandal of Medak district.

It would be possible to make the antibiotic ceftiofur sodium available in injectable form in the regulatory markets with the approval. The company, which has over 180 APIs, has received approvals for most of its formulation facilities from leading regulatory agencies in the US, UK, Canada, WHO and MCC South Africa, according to a press release.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Improved capital flows seen

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line